Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex.

Jaiprasart P, Yeung BZ, Lu Z, Wientjes MG, Cui M, Hsieh CM, Woo S, Au JL.

J Control Release. 2018 Jan 28;270:101-113. doi: 10.1016/j.jconrel.2017.12.001. Epub 2017 Dec 22.

PMID:
29203416
2.

Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships.

Zhao L, Au JL, Wientjes MG.

Curr Cancer Drug Targets. 2017;17(8):735-755. doi: 10.2174/1568009617666170330154054.

3.

Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Au JL, Yeung BZ, Wientjes MG, Lu Z, Wientjes MG.

Adv Drug Deliv Rev. 2016 Feb 1;97:280-301. doi: 10.1016/j.addr.2015.12.002. Epub 2015 Dec 11. Review.

4.

Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.

Wang J, Lu Z, Wang J, Cui M, Yeung BZ, Cole DJ, Wientjes MG, Au JL.

J Control Release. 2015 Oct 28;216:103-10. doi: 10.1016/j.jconrel.2015.08.012. Epub 2015 Aug 10.

5.

Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.

Au JL, Lu Z, Wientjes MG.

AAPS J. 2015 Sep;17(5):1065-79. doi: 10.1208/s12248-015-9785-x. Epub 2015 Jun 19. Review.

6.

Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts.

Cui M, Au JL, Wientjes MG, O'Donnell MA, Loughlin KR, Lu Z.

J Urol. 2015 Jul;194(1):230-7. doi: 10.1016/j.juro.2015.02.036. Epub 2015 Feb 11.

7.

Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin.

Gan Y, Lu J, Yeung BZ, Cottage CT, Wientjes MG, Au JL.

AAPS J. 2015 Jan;17(1):268-76. doi: 10.1208/s12248-014-9703-7. Epub 2014 Nov 26.

8.

Predicting diffusive transport of cationic liposomes in 3-dimensional tumor spheroids.

Wientjes MG, Yeung BZ, Lu Z, Wientjes MG, Au JL.

J Control Release. 2014 Oct 28;192:10-8. doi: 10.1016/j.jconrel.2014.06.050. Epub 2014 Jul 2.

9.

Multiscale tumor spatiokinetic model for intraperitoneal therapy.

Au JL, Guo P, Gao Y, Lu Z, Wientjes MG, Tsai M, Wientjes MG.

AAPS J. 2014 May;16(3):424-39. doi: 10.1208/s12248-014-9574-y. Epub 2014 Feb 26.

10.

Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.

Wang J, Lu Z, Yeung BZ, Wientjes MG, Cole DJ, Au JL.

J Control Release. 2014 Mar 28;178:79-85. doi: 10.1016/j.jconrel.2014.01.012. Epub 2014 Jan 23.

11.

Postoperative adjuvant combination therapy with doxorubicin and noncytotoxic suramin in dogs with appendicular osteosarcoma.

Alvarez FJ, Kisseberth W, Hosoya K, Lara-Garcia A, Kosarek C, Murahari S, Au JL, Wientjes MG, Couto J, Couto G.

J Am Anim Hosp Assoc. 2014 Jan-Feb;50(1):12-8. doi: 10.5326/JAAHA-MS-5958. Epub 2013 Nov 11.

PMID:
24216494
12.

Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors.

Lu Z, Tsai M, Wang J, Cole DJ, Wientjes MG, Au JL.

Curr Cancer Drug Targets. 2014;14(1):70-8.

PMID:
24200079
13.

Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics.

Tsai M, Lu Z, Wientjes MG, Au JL.

J Control Release. 2013 Dec 28;172(3):737-44. doi: 10.1016/j.jconrel.2013.09.011. Epub 2013 Sep 20.

14.

Predictive models of diffusive nanoparticle transport in 3-dimensional tumor cell spheroids.

Gao Y, Li M, Chen B, Shen Z, Guo P, Wientjes MG, Au JL.

AAPS J. 2013 Jul;15(3):816-31. doi: 10.1208/s12248-013-9478-2. Epub 2013 Apr 20.

15.

Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.

Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CL.

Cancer Chemother Pharmacol. 2012 Jul;70(1):49-56. doi: 10.1007/s00280-012-1887-x. Epub 2012 May 22.

16.

Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.

Wang J, Lu Z, Gao Y, Wientjes MG, Au JL.

Nanomedicine (Lond). 2011 Nov;6(9):1605-20. doi: 10.2217/nnm.11.141. Review.

17.

Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability.

Li Y, Wang J, Gao Y, Zhu J, Wientjes MG, Au JL.

AAPS J. 2011 Dec;13(4):585-97. doi: 10.1208/s12248-011-9298-1. Epub 2011 Sep 10.

18.

Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.

Li Y, Wang J, Wientjes MG, Au JL.

Adv Drug Deliv Rev. 2012 Jan;64(1):29-39. doi: 10.1016/j.addr.2011.04.006. Epub 2011 May 3. Review.

19.

Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures.

Wong HL, Shen Z, Lu Z, Wientjes MG, Au JL.

Mol Pharm. 2011 Jun 6;8(3):833-40. doi: 10.1021/mp1004383. Epub 2011 Mar 29.

20.

Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy.

Lu Z, Yeh TK, Wang J, Chen L, Lyness G, Xin Y, Wientjes MG, Bergdall V, Couto G, Alvarez-Berger F, Kosarek CE, Au JL.

J Urol. 2011 Apr;185(4):1478-83. doi: 10.1016/j.juro.2010.11.091. Epub 2011 Feb 19.

21.

Combination intravesical hyperthermia and chemotherapy for bladder cancer.

Au JL, Wientjes MG.

Oncology (Williston Park). 2010 Nov 15;24(12):1155, 1160. No abstract available.

22.

Intraperitoneal therapy for peritoneal cancer.

Lu Z, Wang J, Wientjes MG, Au JL.

Future Oncol. 2010 Oct;6(10):1625-41. doi: 10.2217/fon.10.100. Review.

23.

Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.

Hu L, Wientjes MG, Li J, Au JL.

AAPS J. 2010 Dec;12(4):586-91. doi: 10.1208/s12248-010-9219-8. Epub 2010 Jul 13.

24.

Delivery of siRNA therapeutics: barriers and carriers.

Wang J, Lu Z, Wientjes MG, Au JL.

AAPS J. 2010 Dec;12(4):492-503. doi: 10.1208/s12248-010-9210-4. Epub 2010 Jun 11. Review.

25.

Pancreatic cancer: pathobiology, treatment options, and drug delivery.

Li J, Wientjes MG, Au JL.

AAPS J. 2010 Jun;12(2):223-32. doi: 10.1208/s12248-010-9181-5. Epub 2010 Mar 3. Review.

26.

Comparison of methods for evaluating drug-drug interaction.

Zhao L, Au JL, Wientjes MG.

Front Biosci (Elite Ed). 2010 Jan 1;2:241-9.

27.

Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer.

Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL.

J Pharmacol Exp Ther. 2008 Dec;327(3):673-82. doi: 10.1124/jpet.108.140095. Epub 2008 Sep 9.

28.

Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.

Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL.

Ann Oncol. 2008 Nov;19(11):1903-9. doi: 10.1093/annonc/mdn412. Epub 2008 Jul 15.

29.

Intravesical treatments of bladder cancer: review.

Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL.

Pharm Res. 2008 Jul;25(7):1500-10. doi: 10.1007/s11095-008-9566-7. Epub 2008 Mar 28. Review.

30.

Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance.

Walsh CT, Wei Y, Wientjes MG, Au JL.

J Transl Med. 2008 Jan 18;6:4. doi: 10.1186/1479-5876-6-4.

31.

Biodegradable intraprostatic doxorubicin implants.

Ortiz R, Au JL, Lu Z, Gan Y, Wientjes MG.

AAPS J. 2007 Jun 29;9(2):E241-50.

32.

Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel.

Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, Au JL.

Pharm Res. 2007 Sep;24(9):1691-701. Epub 2007 Apr 20.

33.

Tumor priming enhances delivery and efficacy of nanomedicines.

Lu D, Wientjes MG, Lu Z, Au JL.

J Pharmacol Exp Ther. 2007 Jul;322(1):80-8. Epub 2007 Apr 9.

34.
35.

Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers.

Kosarek CE, Hu X, Couto CG, Kisseberth WC, Green EM, Au JL, Wientjes MG.

J Vet Intern Med. 2006 Sep-Oct;20(5):1172-7.

36.

Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors.

Gan Y, Wientjes MG, Au JL.

Pharm Res. 2006 Jun;23(6):1324-31. Epub 2006 Jun 8.

PMID:
16741658
37.

Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.

Chen D, Song SH, Wientjes MG, Yeh TK, Zhao L, Villalona-Calero M, Otterson GA, Jensen R, Grever M, Murgo AJ, Au JL.

Pharm Res. 2006 Jun;23(6):1265-74. Epub 2006 May 25.

PMID:
16715360
38.

Formulating paclitaxel in nanoparticles alters its disposition.

Yeh TK, Lu Z, Wientjes MG, Au JL.

Pharm Res. 2005 Jun;22(6):867-74. Epub 2005 Jun 8.

PMID:
15948030
39.

Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C.

Xin Y, Lyness G, Chen D, Song S, Wientjes MG, Au JL.

J Urol. 2005 Jul;174(1):322-7.

PMID:
15947683
40.

Intraprostatic chemotherapy: distribution and transport mechanisms.

Wientjes MG, Zheng JH, Hu L, Gan Y, Au JL.

Clin Cancer Res. 2005 Jun 1;11(11):4204-11.

41.

Pentostatin in steroid-refractory acute graft-versus-host disease.

BolaƱos-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC, Lucas DM, Anders V, Phelps M, Grever MR, Vogelsang GB.

J Clin Oncol. 2005 Apr 20;23(12):2661-8.

PMID:
15837980
42.

Suramin as a chemosensitizer: oral pharmacokinetics in rats.

Ogden A, Wientjes MG, Au JL.

Pharm Res. 2004 Nov;21(11):2058-63.

PMID:
15587928
43.
44.

Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy.

Lu Z, Yeh TK, Tsai M, Au JL, Wientjes MG.

Clin Cancer Res. 2004 Nov 15;10(22):7677-84.

45.

Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors.

Song S, Yu B, Wei Y, Wientjes MG, Au JL.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6058-65.

46.

Drug delivery and transport to solid tumors.

Jang SH, Wientjes MG, Lu D, Au JL.

Pharm Res. 2003 Sep;20(9):1337-50. Review.

PMID:
14567626
47.

Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.

Villalona-Calero MA, Wientjes MG, Otterson GA, Kanter S, Young D, Murgo AJ, Fischer B, DeHoff C, Chen D, Yeh TK, Song S, Grever M, Au JL.

Clin Cancer Res. 2003 Aug 15;9(9):3303-11.

48.

Synergy between 3'-azido-3'-deoxythymidine and paclitaxel in human pharynx FaDu cells.

Johnston JS, Johnson A, Gan Y, Wientjes MG, Au JL.

Pharm Res. 2003 Jul;20(7):957-61.

PMID:
12880279
49.

Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents.

Li D, Jang SH, Kim J, Wientjes MG, Au JL.

Pharm Res. 2003 Jan;20(1):45-50.

PMID:
12608535
50.

Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.

Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, Au JL.

Cancer Res. 2003 Feb 1;63(3):579-85.

Supplemental Content

Loading ...
Support Center